UBS Group’s Ambrx Biopharma Inc AMAM Stock Holding History

UBS Group’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-95,400	Closed	-$1.57M	–	10188
2023 Q2	$1.57M	Sell	95,400 -103,400	-52%	-$1.3M	﹤0.01%	3776
2023 Q1	$1.77M	Buy	+198,800	New	+$999K	﹤0.01%	3559

UBS Group's AMAM Position: Q1 2024 in Review

UBS Group sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 3,840 shares — an estimated $54.7K sold.

UBS Group first reported a position in AMAM in Q2 2022 and held it in 6 quarters. The position peaked at $507K in Q1 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

UBS Group reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
UBS Group sold 3,840 Ambrx Biopharma Inc shares in Q1 2024, an estimated $54.7K.
UBS Group first reported a position in Ambrx Biopharma Inc in Q2 2022 and held it in 6 quarters.
UBS Group's Ambrx Biopharma Inc position peaked at $507K in Q1 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.